Femasys (FEMY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.65, -4.90% vs the prior close of $1.74.
- Volume 58.52K shares, 0.1x its 50-day average (light).
- New SEC filings: SCHEDULE 13G (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
FEMY slides 4.9% to $1.65. Closed at $1.65, -4.90% vs the prior close of $1.74. Day range $1.60–$1.77, opened at $1.70.
FEMY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — FEMY slides 4.9% to $1.65
- Closed at $1.65, -4.90% vs the prior close of $1.74. Day range $1.60–$1.77, opened at $1.70.
- Volume was 58.52K shares, 0.1x its 50-day average of 916.65K — lighter than usual.
- Price is -33.2% vs its 50-day average ($2.47) and -75.2% vs its 200-day average ($6.67).
- 52-week range $1.46–$22.20; today's close sits at 1% of that range, 92.6% below the 52-week high.
Oct 15, 2026 — FEMY jumps 11.2% to $1.74
- Closed at $1.74, +11.22% vs the prior close of $1.56. Day range $1.46–$1.81, opened at $1.49.
- Volume was 130.80K shares, 0.1x its 50-day average of 914.64K — lighter than usual.
- Price is -30.5% vs its 50-day average ($2.50) and -74.2% vs its 200-day average ($6.71).
- 52-week range $1.46–$22.20; today's close sits at 1% of that range, 92.2% below the 52-week high.
Oct 14, 2026 — FEMY slides 11.4% to $1.56, a 52-week low
- Closed at $1.56, -11.36% vs the prior close of $1.76. Day range $1.47–$1.75, opened at $1.74.
- Volume was 208.70K shares, 0.2x its 50-day average of 911.44K — lighter than usual.
- Price is -38.2% vs its 50-day average ($2.52) and -76.9% vs its 200-day average ($6.77).
- 52-week range $1.47–$22.20; today's close sits at 0% of that range, 93.0% below the 52-week high.
Oct 13, 2026 — FEMY rises 0.6% to $1.76
- Closed at $1.76, +0.57% vs the prior close of $1.75. Day range $1.67–$1.81, opened at $1.76.
- Volume was 35.50K shares, 0.0x its 50-day average of 911.13K — lighter than usual.
- Price is -31.0% vs its 50-day average ($2.55) and -74.2% vs its 200-day average ($6.83).
- 52-week range $1.67–$22.20; today's close sits at 0% of that range, 92.1% below the 52-week high.
Oct 12, 2026 — FEMY slides 12.5% to $1.75, a 52-week low
- Closed at $1.75, -12.50% vs the prior close of $2.00. Day range $1.71–$2.02, opened at $2.00.
- Volume was 66.50K shares, 0.1x its 50-day average of 910.02K — lighter than usual.
- Price is -32.1% vs its 50-day average ($2.58) and -74.6% vs its 200-day average ($6.89).
- 52-week range $1.71–$22.20; today's close sits at 0% of that range, 92.1% below the 52-week high.
Oct 9, 2026 — FEMY dips 2.2% to $2.00
- Closed at $2.00, -2.20% vs the prior close of $2.05. Day range $1.92–$2.15, opened at $2.10.
- Volume was 128.50K shares, 0.1x its 50-day average of 907.80K — lighter than usual.
- Price is -23.0% vs its 50-day average ($2.60) and -71.3% vs its 200-day average ($6.96).
- 52-week range $1.92–$22.20; today's close sits at 0% of that range, 91.0% below the 52-week high.
Oct 8, 2026 — FEMY rises 2.3% to $2.05
- Closed at $2.05, +2.25% vs the prior close of $2.00. Day range $1.94–$2.11, opened at $1.99.
- Volume was 67.70K shares, 0.1x its 50-day average of 907.01K — lighter than usual.
- Price is -21.8% vs its 50-day average ($2.62) and -70.9% vs its 200-day average ($7.03).
- 52-week range $1.94–$22.20; today's close sits at 1% of that range, 90.8% below the 52-week high.
Oct 7, 2026 — FEMY slides 3.8% to $2.00, a 52-week low
- Closed at $2.00, -3.85% vs the prior close of $2.08. Day range $1.96–$2.05, opened at $2.04.
- Volume was 80.50K shares, 0.1x its 50-day average of 907.05K — lighter than usual.
- Price is -24.0% vs its 50-day average ($2.63) and -71.9% vs its 200-day average ($7.11).
- 52-week range $1.96–$22.20; today's close sits at 0% of that range, 91.0% below the 52-week high.
Oct 6, 2026 — FEMY rises 3.0% to $2.08
- Closed at $2.08, +2.97% vs the prior close of $2.02. Day range $2.01–$2.11, opened at $2.07.
- Volume was 24.10K shares, 0.0x its 50-day average of 908.75K — lighter than usual.
- Price is -21.5% vs its 50-day average ($2.65) and -71.0% vs its 200-day average ($7.18).
- 52-week range $1.96–$22.20; today's close sits at 1% of that range, 90.6% below the 52-week high.
Oct 5, 2026 — FEMY dips 1.5% to $2.02, a 52-week low, 3 down days in a row
- Closed at $2.02, -1.46% vs the prior close of $2.05. Day range $1.99–$2.17, opened at $2.05.
- Volume was 228.40K shares, 0.3x its 50-day average of 904.89K — lighter than usual.
- Price is -24.3% vs its 50-day average ($2.67) and -72.1% vs its 200-day average ($7.25).
- 52-week range $1.96–$22.20; today's close sits at 0% of that range, 90.9% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — FEMY dips 2.4% to $2.05, a 52-week low
- Closed at $2.05, -2.38% vs the prior close of $2.10. Day range $1.96–$2.19, opened at $2.16.
- Volume was 252.60K shares, 0.3x its 50-day average of 900.26K — lighter than usual.
- Price is -24.2% vs its 50-day average ($2.70) and -72.0% vs its 200-day average ($7.32).
- 52-week range $1.96–$22.20; today's close sits at 0% of that range, 90.8% below the 52-week high.
FEMY latest news & SEC filings
Every SEC filing by or about FEMY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 29, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 28, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 3, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $331.83K (prior year $409.27K) (-18.9% vs Jun 30, 2025)
- Net income: -$4.47M (prior year -$4.59M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.33 (prior year -$3.18) (loss narrowed vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mifek Jeffrey Gerald bought 3,125 shares at $3.20 (≈$10.00K) on Aug 7, 2026
- Mifek Jeffrey Gerald bought 3,125 shares at $3.20 (≈$10.00K) on Aug 7, 2026
- Mifek Jeffrey Gerald bought 3,125 shares at $3.20 (≈$10.00K) on Aug 7, 2026
- Mifek Jeffrey Gerald bought 3,125 shares at $3.20 (≈$10.00K) on Aug 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade FEMY
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 31, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.51% (largest 12.5%). That is a volatile stock.
- Liquidity: about 101.27K shares (≈$167.10K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.65 vs a range of $1.46–$22.20 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Jun 8, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 20 open-market buys, 0 sales; latest: John Charles Canning bought 4,375 shares on Aug 7, 2026.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 14, 2026; 8-K Aug 11, 2026.
- Share count: 8.38M shares outstanding (Aug 13, 2026), -74.3% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Surgical & Medical Instruments & Apparatus.
FEMY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.70 | 1.77 | 1.60 | 1.65 | 58.52K |
| Oct 15, 2026 | 1.49 | 1.81 | 1.46 | 1.74 | 130.80K |
| Oct 14, 2026 | 1.74 | 1.75 | 1.47 | 1.56 | 208.70K |
| Oct 13, 2026 | 1.76 | 1.81 | 1.67 | 1.76 | 35.50K |
| Oct 12, 2026 | 2.00 | 2.02 | 1.71 | 1.75 | 66.50K |
| Oct 9, 2026 | 2.10 | 2.15 | 1.92 | 2.00 | 128.50K |
| Oct 8, 2026 | 1.99 | 2.11 | 1.94 | 2.05 | 67.70K |
| Oct 7, 2026 | 2.04 | 2.05 | 1.96 | 2.00 | 80.50K |
| Oct 6, 2026 | 2.07 | 2.11 | 2.01 | 2.08 | 24.10K |
| Oct 5, 2026 | 2.05 | 2.17 | 1.99 | 2.02 | 228.40K |
| Oct 2, 2026 | 2.16 | 2.19 | 1.96 | 2.05 | 252.60K |
| Oct 1, 2026 | 2.17 | 2.24 | 2.10 | 2.10 | 51.90K |
| Sep 30, 2026 | 2.19 | 2.24 | 2.09 | 2.16 | 114.30K |
| Sep 29, 2026 | 2.36 | 2.36 | 2.00 | 2.09 | 277.70K |
| Sep 28, 2026 | 2.42 | 2.48 | 2.35 | 2.38 | 20.70K |
| Sep 25, 2026 | 2.43 | 2.55 | 2.43 | 2.48 | 36.10K |
| Sep 24, 2026 | 2.53 | 2.62 | 2.42 | 2.43 | 103.30K |
| Sep 23, 2026 | 2.60 | 2.60 | 2.50 | 2.58 | 34.10K |
| Sep 22, 2026 | 2.55 | 2.69 | 2.55 | 2.56 | 73.20K |
| Sep 21, 2026 | 2.57 | 2.63 | 2.53 | 2.53 | 32.30K |
About Femasys
Femasys (FEMY) is listed on the Nasdaq and classified by the SEC under “Surgical & Medical Instruments & Apparatus”. Its business address is in SUWANEE, GA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1339005.
FEMY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kenneth D. Eichenbaum | Director | Aug 11, 2026 |
| Charles Larsen | Director | Aug 11, 2026 |
| Kathy Lee-Sepsick | Chief Executive Officer | Aug 11, 2026 |
| Alistair Milnes | Director | Aug 11, 2026 |
| Joshua Silverman | Director | Mar 18, 2026 |
| Edward R Uzialko | Director | Aug 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John Charles Canning | Chief Operating Officer | Aug 11, 2026 |
| Dov Elefant | Chief Financial Officer | Aug 11, 2026 |
| Kathy Lee-Sepsick | Chief Executive Officer | Aug 11, 2026 |
| Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | Aug 11, 2026 |
| Jeremy Alexander Sipos | Chief Technology Officer | Aug 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | John Charles Canning | Buy | 4,375 | $3.20 |
| Aug 7, 2026 | John Charles Canning | Buy | 4,375 | $3.20 |
| Aug 7, 2026 | John Charles Canning | Buy | 4,375 | $3.20 |
| Aug 7, 2026 | John Charles Canning | Buy | 4,375 | $3.20 |
| Aug 7, 2026 | Kathy Lee-Sepsick | Buy | 15,625 | $3.20 |
| Aug 7, 2026 | Kathy Lee-Sepsick | Buy | 15,625 | $3.20 |
| Aug 7, 2026 | Kathy Lee-Sepsick | Buy | 15,625 | $3.20 |
| Aug 7, 2026 | Kathy Lee-Sepsick | Buy | 15,625 | $3.20 |
| Aug 7, 2026 | Jeremy Alexander Sipos | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeremy Alexander Sipos | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeremy Alexander Sipos | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeremy Alexander Sipos | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeffrey Gerald Mifek | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeffrey Gerald Mifek | Buy | 3,125 | $3.20 |
| Aug 7, 2026 | Jeffrey Gerald Mifek | Buy | 3,125 | $3.20 |
FEMY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.29M | $-18.63M | -0.47 | $-18.69M |
| Dec 31, 2024 | $1.63M | $-18.82M | -0.85 | $-19.44M |
| Dec 31, 2023 | $1.07M | $-14.25M | -0.93 | $-11.28M |
| Dec 31, 2022 | $1.21M | $-11.39M | -0.96 | $-10.73M |
| Dec 31, 2021 | $1.18M | $-7.54M | -1.12 | $-7.93M |
Latest balance sheet: total assets $12.29M, total liabilities $8.26M, cash $1.44M (as of Jun 30, 2026).
FEMY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $2.29 |
| May 8, 2026 | 8-K Item 2.02 (results) | $8.60 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $8.40 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $17.96 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $17.86 |
| May 8, 2025 | 8-K Item 2.02 (results) | $23.00 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $26.70 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $20.60 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Surgical & Medical Instruments & Apparatus
Boston Scientific (BSX)Stryker (SYK)3M (MMM)Dexcom (DXCM)Medline (MDLN)Becton Dickinson (BDX)MiniMed (MMED)Resmed (RMD)Insulet (PODD)West Pharmaceutical Services (WST)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on FEMY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.